CAS:135046-48-9 C16H16ClNO2S.H2O4S Clopidogrel hydrogen sulfate
Min.Order / FOB Price:Get Latest Price
| 500 Gram |
Negotiable |
- Min.Order :500 Gram
- Purity: 99%
- Payment Terms : L/C,T/T,
Keywords
CAS:135046-48-9 C16H16ClNO2S.H2O4S Clopidogrel hydrogen sulfate CAS:135046-48-9 C16H16ClNO2S.H2O4S CAS:135046-48-9
Quick Details
- Appearance:white poweder
- Application:CAS:135046-48-9 C16H16ClNO2S.H2O4S
- PackAge:Plastic vacuum packaging bag or bucket
- ProductionCapacity:1|Metric Ton|Day
- Storage:under the cool and dry area
- Transportation:by express or by sea
Superiority:
| Clopidogrel hydrogen sulfate Basic information |
| Product Name: | Clopidogrel hydrogen sulfate |
| Synonyms: | PLAVIX;SR-25990C;CLOPIDOGREL BISULPHATE;CLOPIDOGREL HYDROGEN SULPHATE;CLOPIDOGREL SULPHATE;SR-25990C, Plavix, Methyl (+)-(S)-a-(2-Chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)acetate, Hydrogen sulfate salt;Methyl (S)-alpha-(2-Chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate hydrogen sulfate;SR-25990, Methyl (2-chlorophenyl)(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate hydrogen sulfate |
| CAS: | 135046-48-9 |
| MF: | C16H16ClNO2S.H2O4S |
| MW: | 419.9 |
| EINECS: | |
| Product Categories: | Active Pharmaceutical Ingredients;chiral;Intermediates & Fine Chemicals;Pharmaceuticals;Purinergics P2 receptor |
| Mol File: | 135046-48-9.mol |
|
|
|
| Clopidogrel hydrogen sulfate Chemical Properties |
| mp | 184°C |
| storage temp. | 2-8°C |
| CAS DataBase Reference | 135046-48-9(CAS DataBase Reference) |
| Safety Information |
| Safety Statements | 22-24/25 |
| HazardClass | IRRITANT |
| Clopidogrel hydrogen sulfate Usage And Synthesis |
| Anti-platelet aggregation drug |
Thrombosis caused by arterial atheromatous plaque leads to acute thrombosis cardiovascular and cerebrovascular events. In this pathogenesis, platelets play a central role, which has been fully studied. Clopidogrel hydrogen sulfate is similar to ticlopidine, which is a new anti-platelet aggregation drug, successfully developed by French Sanofi - Synthelabo Fort for the prevention and treatment of heart, brain and other arterial circulation disorders caused by the high blood platelet aggregation, such as recent onset of stroke, myocardial infarction and patients diagnosed with peripheral arterial disease. Many countries have already used it, including United States, Europe and China. This product inhibited platelet activation by inhibiting adenosine diphosphate (ADP) pathway to inhibit platelet aggregation. Since clopidogrel hydrogen sulfate takes several days to achieve effective blood concentration, it does not apply to emergency treatment. Stop using 7 to 10 days, platelet function returned to normal state. The above information is edited by the chemicalbook of Kui Ming. |
| Chemical Properties | Colorless to light yellow liqui |
| Usage | Used as an antithrombotic |
| Usage | platelet aggregation inhibitors |
Details:
| Clopidogrel hydrogen sulfate Basic information |
| Product Name: | Clopidogrel hydrogen sulfate |
| Synonyms: | PLAVIX;SR-25990C;CLOPIDOGREL BISULPHATE;CLOPIDOGREL HYDROGEN SULPHATE;CLOPIDOGREL SULPHATE;SR-25990C, Plavix, Methyl (+)-(S)-a-(2-Chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)acetate, Hydrogen sulfate salt;Methyl (S)-alpha-(2-Chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate hydrogen sulfate;SR-25990, Methyl (2-chlorophenyl)(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate hydrogen sulfate |
| CAS: | 135046-48-9 |
| MF: | C16H16ClNO2S.H2O4S |
| MW: | 419.9 |
| EINECS: | |
| Product Categories: | Active Pharmaceutical Ingredients;chiral;Intermediates & Fine Chemicals;Pharmaceuticals;Purinergics P2 receptor |
| Mol File: | 135046-48-9.mol |
|
|
|
| Clopidogrel hydrogen sulfate Chemical Properties |
| mp | 184°C |
| storage temp. | 2-8°C |
| CAS DataBase Reference | 135046-48-9(CAS DataBase Reference) |
| Safety Information |
| Safety Statements | 22-24/25 |
| HazardClass | IRRITANT |
| Clopidogrel hydrogen sulfate Usage And Synthesis |
| Anti-platelet aggregation drug |
Thrombosis caused by arterial atheromatous plaque leads to acute thrombosis cardiovascular and cerebrovascular events. In this pathogenesis, platelets play a central role, which has been fully studied. Clopidogrel hydrogen sulfate is similar to ticlopidine, which is a new anti-platelet aggregation drug, successfully developed by French Sanofi - Synthelabo Fort for the prevention and treatment of heart, brain and other arterial circulation disorders caused by the high blood platelet aggregation, such as recent onset of stroke, myocardial infarction and patients diagnosed with peripheral arterial disease. Many countries have already used it, including United States, Europe and China. This product inhibited platelet activation by inhibiting adenosine diphosphate (ADP) pathway to inhibit platelet aggregation. Since clopidogrel hydrogen sulfate takes several days to achieve effective blood concentration, it does not apply to emergency treatment. Stop using 7 to 10 days, platelet function returned to normal state. The above information is edited by the chemicalbook of Kui Ming. |
| Chemical Properties | Colorless to light yellow liqui |
| Usage | Used as an antithrombotic |
| Usage | platelet aggregation inhibitors |
You Might Also Like
Related Searches
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View